We found that C5ORF46 positively correlated with TMB and MSI in COAD and STAD, suggesting that high C5ORF46 expression may serve as a marker for immune checkpoint blockade therapy sensitivity in COAD and STAD patients. The gene discussed is C5orf46; the disease is colon adenocarcinoma.